AstraZeneca: positive interim data for lung cancer drug
(CercleFinance.com) - Data from a phase III trial of AstraZeneca's Imfinzi shows that the human antibody - which boosts the immune response to cancer - improved survival for patients with small-cell lung cancer.
A planned interim analysis concluded that the trial has met its primary endpoint by showing a statistically-significant and clinically-meaningful improvement in overall survival in patients treated with Imfinzi in combination with chemotherapy, versus chemotherapy alone.
The trial - which is being conducted in over 200 centres across 22 countries - will now continue to its final analysis, AstraZeneca said.
Lung cancer is the leading cause of cancer death, representing about one-fifth of all cancer deaths worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
A planned interim analysis concluded that the trial has met its primary endpoint by showing a statistically-significant and clinically-meaningful improvement in overall survival in patients treated with Imfinzi in combination with chemotherapy, versus chemotherapy alone.
The trial - which is being conducted in over 200 centres across 22 countries - will now continue to its final analysis, AstraZeneca said.
Lung cancer is the leading cause of cancer death, representing about one-fifth of all cancer deaths worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.